Hello, everyone, how are you today? Unfortunately, it is another cloudy morning in New England, where we are visiting to speak at the American Chemical Society annual gathering (please look here). Nonetheless, our spirits are sunny and we are keeping as busy as ever. So please join us for a cup of stimulation as we scan the news of the world. Hope your day goes well and do stay in touch...
Sanofi-Aventis CEO And His Challenges (The Financial Times)
Roche Inks Deal With Aileron For Stapled Peptides (The New York Times)
Another 115 Pfizer Workers To Lose Their Jobs (The Times Herald-Record)
Novo Nordisk To Test Victoza To Fight Obesity (Dow Jones)
UK's NICE Rejects Avastin Again (PharmaTimes)
Pfizer's Sutent Fails To Meet Goal In Lung Study (Bloomberg News)
Merck Foundation Adds To Botswana AIDS Partnership (Associated Press)
1 Comment
Pardon my ignorance but can someone please explain this?
I know what a NDA is. I know that a sNDA is a supplement to a NDA. I know what an ANDA is. It would go to reason that a sANDA is a supplement to an ANDA, right?
How can a drug maker file a sANDA if it (as the innovator) didn't have an ANDA approval to begin with?
Someone here once told me that there is no such thing as a sANDA, but I have seen documents to the contrary.
Thanks